Loading...
Loading...
Illumina
ILMN today announced the launch of its TruGenome
Undiagnosed Disease Test provided by the CLIA-certified, CAP-accredited
Illumina Clinical Services Laboratory (ICSL). This new service uses
whole human genome sequencing to assist physicians in identifying the
underlying genetic cause of a rare or undiagnosed disease. By providing
physicians with more comprehensive information from a single test, the
service enables a broader understanding of the genetic basis for disease.
The ICSL uses proven Illumina next-generation sequencing technology to
provide a complete picture of the genome. Illumina's team of Ph.D.
geneticists and certified medical geneticists with expertise in
reviewing whole-genome data as it pertains to genetic disease performs
the analysis using Illumina's VariantStudio software for
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in